These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31466832)

  • 21. Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model.
    Lee YK; Oh TJ; Lee JI; Choi BY; Cho HC; Jang HC; Choi SH
    Eur J Pharmacol; 2023 Oct; 957():175946. PubMed ID: 37541370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
    Sa-Nguanmoo P; Tanajak P; Kerdphoo S; Jaiwongkam T; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
    Toxicol Appl Pharmacol; 2017 Oct; 333():43-50. PubMed ID: 28807765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
    Nørgaard SA; Briand F; Sand FW; Galsgaard ED; Søndergaard H; Sørensen DB; Sulpice T
    Eur J Pharmacol; 2019 Oct; 860():172537. PubMed ID: 31310751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dapagliflozin Ameliorates Ovulation Disorders via Attenuating Activated Microglia-Mediated Hypothalamic Inflammation in HFD-Fed Mice.
    Chen X; Xiao Z; Liu Q; Luo D; Cai Y; Fan M
    Neuroendocrinology; 2024; 114(4):331-347. PubMed ID: 38147832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dapagliflozin: A Review in Type 1 Diabetes.
    Paik J; Blair HA
    Drugs; 2019 Nov; 79(17):1877-1884. PubMed ID: 31664708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dapagliflozin attenuates renal gluconeogenic enzyme expression in obese rats.
    Swe MT; Thongnak L; Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Lungkaphin A
    J Endocrinol; 2020 May; 245(2):193-205. PubMed ID: 32092034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Dapagliflozin Treatment on the Expression of Renal Sodium Transporters/Channels on High-Fat Diet Diabetic Mice.
    Ma C; de Baaij JHF; Millar PJ; Gault VA; de Galan BE; Bindels RJM; Hoenderop JGJ
    Nephron; 2019; 142(1):51-60. PubMed ID: 30799406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
    Latva-Rasku A; Honka MJ; Kullberg J; Mononen N; Lehtimäki T; Saltevo J; Kirjavainen AK; Saunavaara V; Iozzo P; Johansson L; Oscarsson J; Hannukainen JC; Nuutila P
    Diabetes Care; 2019 May; 42(5):931-937. PubMed ID: 30885955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methyl dehydroabietate counters high fat diet-induced insulin resistance and hepatic steatosis by modulating peroxisome proliferator-activated receptor signaling in mice.
    Yoshioka H; Mizuno Y; Yamaguchi T; Ichimaru Y; Takeya K; Hitotsuyanagi Y; Nonogaki T; Aoyagi Y
    Biomed Pharmacother; 2018 Mar; 99():214-219. PubMed ID: 29334664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
    Chen H; Tran D; Yang HC; Nylander S; Birnbaum Y; Ye Y
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):443-461. PubMed ID: 32335797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice.
    Millar PJ; Pathak V; Moffett RC; Pathak NM; Bjourson AJ; O'Kane MJ; Flatt PR; Gault VA
    Mol Cell Endocrinol; 2016 Jan; 420():37-45. PubMed ID: 26607806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.
    Terasaki M; Hiromura M; Mori Y; Kohashi K; Nagashima M; Kushima H; Watanabe T; Hirano T
    PLoS One; 2015; 10(11):e0143396. PubMed ID: 26606676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice.
    Omori K; Nakamura A; Miyoshi H; Takahashi K; Kitao N; Nomoto H; Kameda H; Cho KY; Takagi R; Hatanaka KC; Terauchi Y; Atsumi T
    Metabolism; 2019 Sep; 98():27-36. PubMed ID: 31202833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice.
    Wei R; Cui X; Feng J; Gu L; Lang S; Wei T; Yang J; Liu J; Le Y; Wang H; Yang K; Hong T
    Metabolism; 2020 Oct; 111():154324. PubMed ID: 32712220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
    Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
    Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
    Lee DM; Battson ML; Jarrell DK; Hou S; Ecton KE; Weir TL; Gentile CL
    Cardiovasc Diabetol; 2018 Apr; 17(1):62. PubMed ID: 29703207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice.
    Han T; Fan Y; Gao J; Fatima M; Zhang Y; Ding Y; Bai L; Wang C
    Adipocyte; 2021 Dec; 10(1):446-455. PubMed ID: 34550043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats.
    Akahane K; Inoue T; Yokoyama A; Yaguchi A; Ojima K; Kiguchi S; Maruyama K; Kobayashi M; Mori Y
    Drug Res (Stuttg); 2015 Aug; 65(8):416-21. PubMed ID: 25188606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.
    Han S; Hagan DL; Taylor JR; Xin L; Meng W; Biller SA; Wetterau JR; Washburn WN; Whaley JM
    Diabetes; 2008 Jun; 57(6):1723-9. PubMed ID: 18356408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.